

ASAHI INTECC CO., LTD.

Company Profile

February, 2026

(Securities code:7747 Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchange)

Company Profile

Company Name	ASAHI INTECC CO., LTD.
Head Office	3-100 Akatsuki-cho, Seto-shi, Aichi, Japan
Representative	Kenji Miyata, President & CEO
Date of Establishment	July 8, 1976 (Currently, the 50th term)
Business Operations	Development, manufacturing and sale of medical devices Development, manufacturing and sale of ultra-fine stainless steel wire ropes, terminal processed products, etc.
Consolidated net sales	120,025 Mil.Yen (FYE June 2025)
Consolidated operating profit	30,079 Mil. Yen (FYE June 2025)
Capital	18,860 Mil. Yen (FYE June 2025)
Number of Employees	1,212 (Asahi Intecc only) 9,555 (Total)
Affiliated Companies	20 Consolidated subsidiaries, 5 Non-consolidated subsidiaries
R&D bases	Japan, Thailand, US
Manufacturing bases	Thailand, Vietnam, Philippines, China *
Sales bases	Japan, US, Netherlands, France, Germany, Italy, Russia, China, South Korea, Taiwan, Hong Kong, Singapore, Thailand, India, UAE, Brazil, Saudi Arabia
Stock exchange listing	Tokyo Stock Exchange Prime Market, Nagoya Stock Exchange Premier Market (Securities code 7747)

<As of the end of Dec. 2025>

* Regarding the China factory, operation is scheduled to start around December 2030.

Global Network – R&D/Production (Coexistence of Japan & Overseas)



**GLOBAL HEADQUARTERS
AND R&D CENTER
(Product R&D)**



**THAILAND :
ASAHI INTECC THAILAND CO., LTD.**



**VIETNAM :
ASAHI INTECC HANOI CO., LTD.**



**China:
Asahi Ina Medical Equipment
(Nanning) Co., Ltd.**

※Scheduled to begin operations around
December 2030.



**PHILIPPINES :
TOYOFLEX CEBU CORPORATION**


**Production 3 Bases
1 Base in Preparation**

**【OVERSEAS】
Production bases**


**【JAPAN】
R&D/Prototype**

Japan conducts R&D and prototyping; mass production takes place in overseas factories.

Sales Bases



R&D Bases



Business Fields and Divisions

■ FYE June 2025

Revenue 120,025Mill. Yen

Operating income 30,079Mill. Yen

Medical Division
(**Medical Brand / Medical OEM**)

Medical Field
(approx. 96%)

Industrial Field
(approx. 4%)


Device Division
(**Medical Components / Industrial Components**)



Expanding from the Industrial Components Field to the Medical Device Field

Leveraging the ultra-fine stainless steel wire rope technology cultivated in the industrial components field, we have entered the medical device field. In particular, the overseas market for the medical division has grown significantly.

(Unit: Mil.Yen)
140,000



Business Overview and Main Product Groups

Starting from the manufacturing of wire ropes for industrial machine, expanding business into the medical device field (Access devices)

Device Division 10%

Medical Division 90%

Industrial Field 4%

Medical Field 96%

Industrial components



Medical components



Materials for Endoscopic Treatment Devices)



Own Brand Products / OEM Supply


Therapeutic Access Devices

OEM Supply



Main products

account for about 50% of sales



<< Markets Where Used >>



Founded

Entered medical device business in 1994

Main Products of Medical Device

Guide Wires and Catheters for Treatment

Cardiovascular

- **PCI Guide Wires**
- PCI Guiding Catheters
- PCI Balloon Catheters
- Penetration Catheters

Peripheral Vascular, Abdominal Vascular, Cerebrovascular Systems







- Peripheral Guide Wires
- IVR Guide Wires
- Cerebrovascular System Guide Wires

Guide Wires and Catheters for Examination

- Guide Wires for Angiography
- Catheters for Angiography

OEM supplies

- Products other than Cardiovascular Catheters





Our main product at **48.2%** (FYE June 2025) of Revenue

PCI (Percutaneous Coronary Intervention)-1

- Therapy for coronary artery disorder (angina, myocardial infarction)
- Recover the blood flow after dilatation of stenosed lesion
- Treatment through femoral or radial artery without laparotomy and thoracotomy to minimize the mental and physical burden on patients.

Surgical Therapy

Bypass Operation



Interventional Therapy

Minimally Invasive Treatment (PCI Treatment)




PCI (Percutaneous Coronary Intervention)-2

For PCI treatment to be successful, the PCI guidewire must reach the affected area


① PCI GW Advancement

Small size tube called PCI Guiding Catheter inserted in blood vessel. Advance PCI GW inside of this tube.




② PCI Balloon Catheter Tracking

Along with PCI GW, PCI Balloon Catheter trucked over PCI GW to the point of the narrowed portion of vessel.





③ PCI Balloon Catheter dilatation

Dilate Balloon, then enlarge the blood vessel.



④ PCI Balloon Catheter pulled out

After Narrow portion enlarged then blood flow to recover.




PCI (Percutaneous Coronary Intervention)-3

Comparatively easy lesions




Lesions with high difficulty



Market Trend: Market Share of Our Main Product PCI GW [FYE June 2025]

(Our estimate)



Continue to strive to expand market share in all regions

Technological Advantages: 4 Core Technologies

High transmissibility of rotation(Torquability)



Tip flexibility(Safe operation)



Doctors manipulate the wire and try to transfer the feeling of finger tip to the distal end of wire.

Source of competitiveness: 4 core technologies

Control of hardness and diameter



Wire drawing technology

Wire forming technology

Micron-level molding



Integrated production system handling materials down to the finished products

Rotation following capacity



Torque technology

Resin coating technology


Ultra-thin film coating



Our Company's Flagship CTO Treatment: Implementation of PCI Treatment in CTO Cases

■ What is CTO ? (Chronic Total Occlusion)

- A disease of hard calcification
- Completely clogged up blood vessel



【 Level of heart disease 】

Healthy person → Risk holder

Lifestyle-related diseases

Cardiovascular occlusion

CTO

(Chronic Total Occlusion)

Latent patient

Previously realm of surgical operations


In the era when the Japanese market depended on imports for PCI GW, Japanese KOL requested major manufacturers to make a wire for CTO PCI but were turned down.

※KOL(Key Opinion Leader)・・・A physician with influence over the direction of PCI.


PCI GW for CTO Procedures (1995)

Aggressive expansion of CTO cases via minimally invasive procedures

Our Strength: Competitive Power in Medical Devices” Based on “High Technology for Raw Material



Our Strength: Merits of Segmental Structure (fusion/combination/circulation)



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-56-1851

URL <https://www.asahi-intecc.co.jp/en>